πŸ‡ΊπŸ‡Έ FDA
Patent

US 10842801

Optimizing mifepristone absorption

granted A61KA61K31/567A61K31/575

Quick answer

US patent 10842801 (Optimizing mifepristone absorption) held by Corcept Therapeutics Incorporated expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/567, A61K31/575